BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Aragon Pharmaceuticals, Inc. (Acquired by Johnson & Johnson) 

12780 El Camino Real
Suite 301
San Diego  California  92130  U.S.A.
Phone: 858-369-7600 Fax: 858-369-7650


SEARCH JOBS





Segment
Pharmaceuticals





 Company News
Johnson & Johnson (JNJ) Completes Acquisition of Aragon Pharmaceuticals, Inc. 8/20/2013 9:36:39 AM
Johnson & Johnson (JNJ) to Buy Aragon Pharmaceuticals, Inc. for Up to $1 Billion 6/17/2013 7:06:06 AM
Aragon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase I Study of ARN-810 in Estrogen Receptor Positive Breast Cancer 4/4/2013 9:22:28 AM
Aragon Pharmaceuticals, Inc. Announces Key Strategic Hire 2/11/2013 9:25:19 AM
Aragon Pharmaceuticals, Inc. Wins Key Legal Ruling Against Medivation, Inc. (MDVN) 1/4/2013 7:20:44 AM
Aragon Pharmaceuticals, Inc. Snags $50 Million Series D 10/4/2012 6:18:41 AM
Aragon Pharmaceuticals, Inc. Announces Clinical Results from Ongoing Phase II Trial Confirming Robust Anti-Tumor Activity and Tolerability of ARN-509 in Three Different Patient Populations of Castration Resistant Prostate Cancer 10/1/2012 10:54:43 AM
Aragon Pharmaceuticals, Inc. Raises $50 Million 10/1/2012 7:24:06 AM
Aragon Pharmaceuticals, Inc. Announces Appointment of Faheem Hasnain as Independent Director 8/28/2012 10:49:42 AM
Aragon Pharmaceuticals, Inc. Nabs $42 Million, Targets Hormone-Driven Cancers 3/6/2012 6:33:37 AM
12